Tarcocimab
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Retinopathy
Conditions
Diabetic Retinopathy
Trial Timeline
May 1, 2024 → Jan 31, 2026
NCT ID
NCT06270836About Tarcocimab
Tarcocimab is a phase 3 stage product being developed by Kodiak Sciences for Diabetic Retinopathy. The current trial status is active. This product is registered under clinical trial identifier NCT06270836. Target conditions include Diabetic Retinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06270836 | Phase 3 | Active |
Competing Products
20 competing products in Diabetic Retinopathy